# Core 3: The Affinity Reagent Characterization Core

> **NIH NIH U19** · UNIVERSITY OF WASHINGTON · 2021 · $497,365

## Abstract

Abstract
Affinity reagents are essential to almost any modern scientific investigation of human disease. Antibodies are
the most widely used family of affinity reagents and when cloned and produced in culture represent a powerful
tool that can be continually regenerated. Many monoclonal antibodies boast strong interactions, slow off-rates,
and good specificity. To supplement monoclonal antibodies, the Baker laboratory at the University of
Washington has developed techniques to design small proteins de novo that bind molecules of interest. The
overall goal of this Core entitled, “Affinity Regent Characterization Core,” is to provide the reagents needed for
Projects 2 and 3 by (1) developing new monoclonal antibodies to be used in different assays, (2) labeling
antibodies and novel small protein affinity reagents for use in CyTOF and brain imaging, and (3) carefully
characterizing each reagent to ensure that different batches of affinity reagents behave similarly.

## Key facts

- **NIH application ID:** 10105260
- **Project number:** 5U19AG065156-02
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** ANDREW N HOOFNAGLE
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $497,365
- **Award type:** 5
- **Project period:** 2020-02-15 → 2025-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10105260

## Citation

> US National Institutes of Health, RePORTER application 10105260, Core 3: The Affinity Reagent Characterization Core (5U19AG065156-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10105260. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*